3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
3
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Non-Hodgkin
3
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Myeloid, Acute
2
Hodgkin Disease
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Sezary Syndrome
1
Renal Insufficiency
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Intraocular Lymphoma
1
Immunoblastic Lymphadenopathy
1
Hematologic Neoplasms
1
Interventions
Rituximab
66
Cyclophosphamide
52
fludarabine phosphate
26
fludarabine
22
Filgrastim
21
Vincristine
19
Methotrexate
19
Melphalan
19
Doxorubicin
18
Radiotherapy
17
Etoposide
17
Prednisone
16
Tacrolimus
15
Whole-Body Irradiation
14
Mycophenolic Acid
14
Cytarabine
14
Peripheral Blood Stem Cell Transplantation
13
Gemcitabine
13
Cyclosporine
13
Antilymphocyte Serum
13
Lenalidomide
12
Busulfan
11
Bortezomib
11
Granulocyte Colony-Stimulating Factor
9
Alemtuzumab
9
sargramostim
8
Dexamethasone
8
Cord Blood Stem Cell Transplantation
8
pembrolizumab
7
ibritumomab tiuxetan
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma
×
belinostat
×
Clear all
NCT00274651
2015-07-28
PXD101-CLN-6
Valerio Therapeutics
Phase 2
Terminated
53 enrolled
12 charts